Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 01 Aug 2022
PBS listings will help people with spinal muscular atrophy, schizophrenia and multiple sclerosis
1 August 2022 - From today, Australians will have access to new and updated PBS listings, including a new spinal ...
Posted by Michael Wonder on 01 Aug 2022
TGA approves new medicine for NSCLC patients with an EGFR exon 20 mutation
1 August 2020 - First medicine approved by the TGA for this mutation. ...
Posted by Michael Wonder on 31 Jul 2022
FDA provides update on agency response to monkeypox outbreak
29 July 2022 - Today, the U.S. FDA is providing an update on its multi-pronged response to monkeypox in the United ...
Posted by Michael Wonder on 31 Jul 2022
U.S. would gain power to negotiate drug prices under Manchin-Schumer Bill
31 July 2022 - Legislation would also cap out of pocket drug costs for Medicare beneficiaries at $2,000 a year. ...
Posted by Michael Wonder on 31 Jul 2022
Schedule of Pharmaceutical Benefits - 1 August 2022
1 August 2022 - The August 2022 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. ...
Posted by Michael Wonder on 31 Jul 2022
2022 October price disclosure cycle – patient savings
29 July 2022 - Indicative brand price reductions and patient savings resulting from the 2022 October Cycle of Price Disclosure have ...
Posted by Michael Wonder on 31 Jul 2022
Gilead Sciences statement on FDA acceptance of new drug application for investigational lenacapavir
27 July 2022 - Gilead Sciences today announced that the U.S. FDA accepted for review the new drug application resubmission for ...
Posted by Michael Wonder on 31 Jul 2022
New Zealand Pharmaceutical Schedule - 1 August 2022
1 August 2022 - The August 2022 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 30 Jul 2022
Amylyx Pharmaceuticals announces Albrioza is now available in Canada for the treatment of amyotrophic lateral sclerosis
29 July 2022 - Amylyx Pharmaceuticals today announced that Albrioza (sodium phenylbutyrate and ursodoxicoltaurine) is now commercially available in Canada for ...
Posted by Michael Wonder on 30 Jul 2022
FDA approves Arcutis Zoryve (roflumilast) 0.3% cream for the treatment of plaque psoriasis in individuals age 12 and older
29 July 2022 - Commercial product expected to be available by mid August. ...
Posted by Michael Wonder on 29 Jul 2022
Rinvoq (upadacitinib) approved by European Commission as an oral treatment for adults with active non-radiographic axial spondyloarthritis
29 July 2022 - Approval is supported by data from the Phase 3 SELECT-AXIS 2 pivotal clinical trial in which ...
Posted by Michael Wonder on 29 Jul 2022
ATAGI update following weekly COVID-19 meeting (27 July 2022)
29 July 2022 - An update from the Australian Technical Advisory Group on Immunisation following their weekly meeting on 27 July ...
Posted by Michael Wonder on 28 Jul 2022
Drug industry poised for rare political loss on prices
28 July 2022 - Senate deal giving Medicare limited authority to negotiate prices would chip at power of Big Pharma. ...
Posted by Michael Wonder on 28 Jul 2022
ImmunityBio announces FDA acceptance of biologics license application for N-803 in BCG-unresponsive non-muscle invasive bladder cancer carcinoma in situ
28 July 2022 - This acceptance represents the first regulatory filing for N-803, an IL-15 superagonist, which was granted breakthrough therapy ...
Posted by Michael Wonder on 28 Jul 2022
Is private health insurance worth it? More people say yes
28 July 2022 - Amid rising interest rates and warnings of an economic slowdown, more Australians are turning to private ...